BridgeMD
New treatment option for Acute-On-Chronic Liver Failure
Official title COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device
ClinicalTrials.gov ID: NCT06079021
What this study is testing
- What it's testing
- A Prospective, Single-Center trial, in Patients With Acute on Chronic Liver Failure. Study of Standard Medical Care Plus CytoSorb® Compared to Standard Medical Care Alone in a historical group.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- adult patients (≥ 18 years) admitted to the University Hospital of Antwerp (UZA), Belgium.
- Written informed consent from patient or if not possible due to encephalopathy (\> grade 2): legal representative
- acute-on-chronic liver failure (ACLF) grade ≥ 2:
- Acute decompensation event (identifiable trigger)
- Hepatic encephalopathy grade ≥ 2
You likely can't join if
- known patient will against participation in the study or against the measures applied in the study
- a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours
- no complete remission of malignancy including hepatocellular carcinoma within the past 12 months
- ongoing intermittent or CRRT before study inclusion
See the full eligibility criteria
- adult patients (≥ 18 years) admitted to the University Hospital of Antwerp (UZA), Belgium.
- Written informed consent from patient or if not possible due to encephalopathy (\> grade 2): legal representative
- acute-on-chronic liver failure (ACLF) grade ≥ 2:
- Acute decompensation event (identifiable trigger)
- Hepatic encephalopathy grade ≥ 2
- Acute kidney injury (AKI) according to Kidney Disease: Improving Global Outcome (KDIGO) criteria stage 3 (≥ 3-fold increase of serum creatinine OR increase of serum creatinine to ≥ 4 mg/dl OR urine output ≤ 0.3 ml/kg/h...
- Serum bilirubin ≥ 10 mg/dl
- Hemodynamic instability with vasopressor support (norepinephrine \> 0.05 mcg/kg/min)
- known patient will against participation in the study or against the measures applied in the study
- a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours
- no complete remission of malignancy including hepatocellular carcinoma within the past 12 months
- ongoing intermittent or CRRT before study inclusion
The study team makes the final eligibility decision.
Where it's taking place
- Edegem, Antwerp, Belgium
Compensation & support
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Edegem, Antwerp, Belgium. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.